Although there are numerous reported pathogenic variants driving tumorigenicity and the distinctly presented spatial phenotypes in meningioma patients, below we focus on the role of neurofibromatosis type 2 (NF2) and TNF receptor-associated factor 7 (TRAF7) mutations driving tumorigenicity across convexity and skull-base meningiomas, respectively. This evidence concerns the gene NF2 and skull base meningioma.